PMID- 16893500
OWN - NLM
STAT- MEDLINE
DCOM- 20061212
LR  - 20060808
IS  - 1672-7681 (Print)
IS  - 1672-7681 (Linking)
VI  - 3
IP  - 3
DP  - 2006 Jun
TI  - Dendritic cell as therapeutic vaccines against tumors and its role in therapy for 
      hepatocellular carcinoma.
PG  - 197-203
AB  - Dendritic cells (DCs) are the most potent professional antigen-presenting cells, 
      and capable of stimulating naive T cells and driving primary immune responses. 
      DCs are poised to capture antigen, migrate to draining lymphoid organs, and after 
      a process of maturation, select antigen-specific lymphocytes to which they 
      present the processed antigen, thereby inducing immune responses. The development 
      of protocols for the ex vivo generation of DCs may provide a rationale for 
      designing and developing DC-based vaccination for the treatment of tumors. There 
      are now several strategies being applied to upload antigens to DCs and manipulate 
      DC vaccines. DC vaccines are able to induce therapeutic and protective antitumor 
      immunity. Numerous studies indicated that hepatocellular carcinoma (HCC) 
      immunotherapies utilizing DC-presenting tumor-associated antigens could stimulate 
      an antitumour T cell response leading to clinical benefit without any significant 
      toxicity. DC-based tumor vaccines have become a novel immunoadjuvant therapy for 
      HCC.
FAU - Sun, Kang
AU  - Sun K
AD  - Department of General Surgery, the First Affiliated Hospital of Soochow 
      University, Suzhou 215006, China.
FAU - Wang, Liang
AU  - Wang L
FAU - Zhang, Yanyun
AU  - Zhang Y
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Cell Mol Immunol
JT  - Cellular & molecular immunology
JID - 101242872
RN  - 0 (Antigens, Neoplasm)
SB  - IM
MH  - Animals
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/*immunology
MH  - Carcinoma, Hepatocellular/*immunology/*therapy
MH  - Dendritic Cells/immunology/*transplantation
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Liver Neoplasms/*immunology/*therapy
RF  - 66
EDAT- 2006/08/09 09:00
MHDA- 2006/12/13 09:00
CRDT- 2006/08/09 09:00
PHST- 2006/08/09 09:00 [pubmed]
PHST- 2006/12/13 09:00 [medline]
PHST- 2006/08/09 09:00 [entrez]
PST - ppublish
SO  - Cell Mol Immunol. 2006 Jun;3(3):197-203.